Key Takeaways
- Strong quarter, H2 caution: Revenue grew 33% YoY to INR1,794 crores with PAT up 49%, but management explicitly guided for lower H2 margins as US competition builds and institutional sales normalize.
- US generics is the swing factor: H1 revenue surged 49% YoY on a limited-competition product, but new entrants have now arrived, so sales will normalize and full-year guidance is only high single digits (revised from mid-single digits).
- Asia branded generics snapped back: Q2 grew 18% YoY after a depressed Q1, as logistics disruptions from Middle East geopolitical tensions were resolved and deferred sales materialized; full-year mid-teens growth guidance is intact.
- Africa Institution windfall will not repeat: Q2 sales jumped 259% YoY on strong but unpredictable procurement; management does not expect the same level to sustain in H2.
- What to watch next quarter: The pace of US sales normalization, whether Asia and Africa branded generics momentum holds, and the magnitude of the guided H2 margin compression.
US Generics: The Boom, the Normalization, and the Pipeline
- H1 surge driven by one product: A limited-competition product that began driving elevated sales in H2 of the previous year continued through Q2 FY27, producing 49% YoY H1 growth to INR971 crores.
- Competition has now arrived: New players have entered for that product, which will reduce Ajanta's market share and normalize sales going forward; full-year revenue growth guidance was revised up to high single digits from mid-single digits, implying a materially lower H2 run rate.
- Long-term US strategy unchanged: The company plans to file 5 to 6 ANDAs annually with a target of 8 to 10, focusing on complex products like delayed-release and extended-release formulations; more than 15 to 20 products are under development at any time, and a few more approvals are expected in the next two quarters.
- No Para 4 filings planned among the five to seven US filings targeted.
- US profitability improved significantly, reflected in the 49% PAT growth, though management declined to disclose whether US margins are now in line with corporate level.
Yogesh Agrawal: "From the last year second half onwards, we had a product which had a limited competition situation, and we continued that for second half of the last year, and currently this first two quarters... the new competition has come in for this product, so we are expecting our market share for this product to be reduced, and because of that, the sales will get normalized for the US going forward in the next quarters."
India Branded Generics: Outpacing the Market
- Broad-based growth: Q2 sales grew 16% YoY to INR504 crores, H1 up 20% to INR1,013 crores, outperforming IPM growth of 13% per IQVIA MAT September 2026; Ajanta's MAT growth was 17% per IQVIA, with volume growth at 18% ahead of the market.
- Field force productivity jumped: PCPM improved to INR4.5 lakhs in H1 from INR3.7 lakhs in FY2026.
- Structural tailwinds aiding Rx growth: Hospital penetration is improving, government schemes and insurance coverage are driving prescriptions, and a slowdown in the unbranded generics segment is adding back to Rx distribution growth.
- Therapy-wise performance: On a MAT basis, Ajanta is growing much faster than IPM in ophthalmology, derma, and pain; cardiovascular is almost on par or just marginally better; gynaecology and nephrology bases remain too small for meaningful commentary.
- Overall IPM ranking improved to 23rd in September 2026 from 24th in March 2026.
- NLEM risk is zero: Products under NLEM are only in the oncology segment, where Ajanta does not operate.
Rajesh Agrawal: "One of the things that's happening perhaps is the slight bit of slowdown in the growth of the generic, unbranded generic segment, which we saw taking off for the last two three years. Has kind of slowed down a little bit. So that's adding back to the RX distribution growth."
Emerging Markets: Asia Recovers, Africa Delivers, Institutions Surge
- Asia branded generics Q2 bounce-back: Q2 sales grew 18% YoY to INR366 crores after a depressed Q1 of INR255 crores, because supply chain and logistics challenges from Middle East geopolitical tensions were ironed out, alternative shipping routes were leveraged, and some sales pushed out from Q1 materialized in Q2; H1 growth was only 1% YoY due to the Q1 drag.
- Africa branded generics momentum: Q2 sales up 41% YoY, H1 up 35% YoY, driven by market share gains, new product launches, field force additions over the last 2 to 3 years now becoming more productive, and favorable currency movement.
- Africa Institution business windfall: Q2 sales surged 259% YoY to INR116 crores, H1 up 164% to INR187 crores, due to strong procurement activity by institutional agencies; management does not expect the same level to sustain in H2 given inherent unpredictability of timing and value.
- Field force expansion continues: More than 100 people were added in emerging markets in H1, increasing field size by about 5%; full-year plan is to increase by around 7% to 8%, driven by gaps and the need for more people as more products launch.
- Asia growth drivers beyond existing geographies: A good product pipeline under registration and R&D development will drive growth via new product introductions; the company is also actively looking at new markets in the Middle East and mid-stage markets.
- Historical context: Asia and Africa have delivered around 13% to 15% CAGR over the last three years, with year-to-year variations largely driven by external factors like geopolitical issues.
Yogesh Agrawal: "The challenges we faced last year and the first quarter was more of a logistics and supply chain, not really the demand or our ability to increase the business or get the market share. As those two challenges are behind us, we are confident that we should be able to post good results in the existing."
Margins: Strong H1, Guided H2 Compression
- Q2 EBITDA margin came in at 30% versus 27% YoY, helped by no forex loss in the quarter; H1 adjusted EBITDA margin was 29%.
- Gross margin improved to 79% in Q2 and H1, up over FY2026 primarily due to favorable currency.
- Costs rose in line with growth: Personnel costs up 21% YoY in Q2 and 23% in H1 on annual increments, field force expansion, and additional manpower and manufacturing facilities; other expenses up 23% YoY in Q2 and 27% in H1, reflecting higher selling expenses, international logistics, manufacturing costs, and strategic investments.
- H1 other income of INR108 crores included a forex gain of INR69 crores; net forex effect for H1 was a gain of INR43 crores after a loss of INR26 crores in other expenses.
- H2 margin compression is explicit guidance: EBITDA margins are expected to be lower in H2 than H1 as US competition builds, institutional sales normalize, and investment in R&D and field force steps up.
- Working capital improved: Trade receivable days reduced from 125 to 100 days due to better collection in the US business; inventory days reduced from 63 to 52 days; ROCE improved from 33% to 41% and RONW from 25% to 31%.
- By year-end, receivables may show some improvement but inventory is expected to go back to March 2026 levels, so overall working capital should be similar to last year's close.
Arvind Agrawal: "This implies a lower margin in the second half than in the first as competition in the US builds, institutional sales normalize, and we step up investment in R&D and our field force."
New Bets: Semaglutide, New Therapies, and the Long Game
- Semaglutide in-licensing: Dossier filings have just started across a large number of countries; sales should start coming in FY28 with an approval lead time averaging around two years; the revenue impact will trickle in across small, medium, and large countries rather than arriving as a one-go full-blown launch.
- New therapy entries: The company entered gynaecology last year; it is gaining momentum and viewed as a three-to-five-year progression; management keeps evaluating new therapy areas and will enter when a great go-to-market strategy is in place.
- India therapy growth expectations: Management stated they will be able to maintain current growth rates across specialties for the remainder of FY27.
- Emerging markets long-term framing: Management emphasized that the Ajanta story should be seen on a three-year horizon and beyond, not quarter-to-quarter, given that external factors can depress or elevate any single quarter.
Yogesh Agrawal: "Ajanta story is not a quarter story. Ajanta story is not two quarter story. It is not one year story. It has to be seen in a three year horizon and plus. So we could have a quarter where the sales are slightly depressed, next quarter elevated, but if you see average over year-over-year, three year trajectory, we've been able to post good growth."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | High teens | FY27 full year |
| Gross margin | ~78% ±100 bps | FY27 full year |
| EBITDA margin | ~27% ±100 bps | FY27 full year |
| R&D spend | ~5% of revenue | FY27 full year |
| Effective tax rate | ~26.5% | FY27 full year |
| Capex | ~INR400 crores | FY27 full year |
| US generics revenue growth | High single digits | FY27 full year |
| Asia branded generics growth | Mid-teens | FY27 full year |
| Africa branded generics growth | High double digit | FY27 full year |
| India branded generics growth | Mid-teens, 20–25% faster than IPM | FY27 full year |
| H2 EBITDA margin | Lower than H1 | H2 FY27 |
| US sales run rate | Normalize downward as competition enters | H2 FY27 |
| Africa Institution sales | Not expected to sustain at H1 levels | H2 FY27 |
| Emerging markets field force | Increase by ~7% to 8% | FY27 full year |
| Semaglutide revenue contribution | Sales to begin, trickling in across countries | FY28 onwards |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹1,794 cr, up 33% YoY |
| EBITDA | ₹543 cr, up 47% YoY; margin 30% vs 27% YoY |
| Profit after tax | ₹388 cr, up 49% YoY; margin ~22% of revenue |
| Gross margin | 79%, same for H1; FY27 guidance around 78% ±100 bps |
| Personnel costs | ₹384 cr, up 21% YoY |
| R&D expenditure | ₹72 cr, ~4% of revenue; FY27 guidance around 5% with H2 step-up |
| Other expenses | ₹483 cr, up 23% YoY; no forex loss in Q2 |
| Other income | ₹42 cr, includes forex gain of ₹24 cr |
| Effective tax rate | 26.5% for H1, expected around this level for full year |
| ROCE | 41% as at end of September 2026, improved from 33% in March 2026 |
| RONW | 31% as at end of September 2026, improved from 25% in March 2026 |
| Net cash and investments | ₹574 cr as at September 2026, after paying interim dividend of ~₹400 cr |
| Trade receivable days | 100 days, reduced from 125 days in March 2026 |
| Inventory days | 52 days, reduced from 63 days in March 2026 |
| India business revenue | ₹504 cr, up 16% YoY; contributed 28% of total Q2 revenue |
| India field force productivity (PCPM) | ₹4.5 lakhs in H1, vs ₹3.7 lakhs in FY2026 |
| India IPM ranking | 23rd in September 2026, improved from 24th in March 2026 |
| India IQVIA growth | 17% MAT September 2026, vs IPM growth of 13% |
| India volume growth | 18%, ahead of overall market |
| India new product launch growth | exceeded market by 70% |
| India therapy mix | Cardiology 37%, ophthalmology 28%, dermatology 22%, pain management 10%, newer therapies 3% |
| India trade generics revenue | ₹56 cr in Q2 |
| Asia branded generics revenue | ₹366 cr, up 18% YoY; 4 new products launched in H1 |
| Africa branded generics revenue | ₹312 cr, up 41% YoY; 3 new products launched in H1 |
| US generics revenue | ₹484 cr, up 41% YoY; constant currency growth ~30-35% |
| US generics ANDA pipeline | 17 ANDAs pending approval; 3 products launched, 4 final approvals, 1 ANDA filed in H1 |
| Africa Institution business revenue | ₹116 cr, up 259% YoY |
| FY27 revenue growth guidance | high teens, unchanged |
| FY27 US generics growth guidance | high single digits, revised from mid-single digit |
| FY27 EBITDA margin guidance | around 27% ±100 bps |
| FY27 capex guidance | around ₹400 cr, including ~₹150 cr maintenance |
| H1 capex | ₹210 cr |
| Emerging markets field force | ~2,500 MRs, up from 2,400 last year; ~5% increase in H1, full-year guidance 7-8% |
| Emerging markets MR productivity | ~₹8 lakhs and above per annum |
| H1 net forex effect | gain of ₹43 cr (₹69 cr gain in other income less ₹26 cr loss in other expenses) |
| H2 EBITDA margin implied | ~26% (per an analyst's math) |